NPTH — NeuPath Health Income Statement
0.000.00%
- CA$18.84m
- CA$27.48m
- CA$72.81m
- 55
- 94
- 86
- 93
Annual income statement for NeuPath Health, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 47.6 | 60.9 | 62.7 | 66.1 | 72.8 |
| Cost of Revenue | |||||
| Gross Profit | 9.72 | 11.1 | 10.8 | 12.3 | 13.9 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 52 | 64.1 | 66.8 | 66.8 | 72.1 |
| Operating Profit | -4.4 | -3.28 | -4.1 | -0.712 | 0.692 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -4.86 | -3.25 | -4.08 | 0.055 | -0.273 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -5.06 | -3.23 | -4.28 | -0.191 | -0.485 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -5.06 | -3.23 | -4.14 | -0.107 | -0.728 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -5.06 | -3.23 | -4.14 | -0.107 | -0.728 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.15 | -0.063 | -0.058 | -0.008 | -0.004 |